The role of palliative radiation therapy in symptomatic locally advanced gastric cancer

2007 ◽  
Vol 67 (2) ◽  
pp. 385-388 ◽  
Author(s):  
Jeremy Tey ◽  
Michael F. Back ◽  
Thomas P. Shakespeare ◽  
Rahul K. Mukherjee ◽  
Jiade J. Lu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Radiation Therapy ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Palliative Radiation ◽  
Locally Advanced Gastric Cancer ◽  
Palliative Radiation Therapy

scholarly journals Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

2016 ◽  
Vol 115 (6) ◽  
pp. 655-663 ◽  
Author(s):  
Patricia Martin-Romano ◽  
Jose J Sola ◽  
Juan A Diaz-Gonzalez ◽  
Ana Chopitea ◽  
Yohana Iragorri ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Locally Advanced Gastric Cancer ◽  
Regression Grade ◽  
Histological Regression

Clinical benefit of palliative radiation therapy in advanced gastric cancer

2008 ◽  
Vol 47 (3) ◽  
pp. 421-427 ◽  
Author(s):  
Michelle M. Kim ◽  
Michelle M. Kim ◽  
Vishal Rana ◽  
Nora A. Janjan ◽  
Michelle M. Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Radiation Therapy ◽  
Advanced Gastric Cancer ◽  
Clinical Benefit ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy

scholarly journals ANALYSIS OF HEMATOLOGIC, HEPATIC AND PANCREATIC TOXICITY DURING NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER

2018 ◽  
Vol 17 (3) ◽  
pp. 20-27 ◽  
Author(s):  
V. Yu. Skoropad ◽  
D. D. Kudryavtsev ◽  
E. N. Anikina ◽  
M. V. Poluaktova ◽  
L. N. Titova
Keyword(s):  
Gastric Cancer ◽  
Radiation Therapy ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Chemoradiotherapy ◽  
Subtotal Resection ◽  
Combined Modality Treatment ◽  
Symptomatic Therapy ◽  
Locally Advanced Gastric Cancer ◽  
Pancreatic Toxicity

Purpose.We analyzed the frequency and severity of hematologic, hepatic and pancreatic toxicity during and after completion of neoadjuvant chemoradiotherapy in patients with gastric cancer.Material and methods. Phase II clinical trial was conducted to  evaluate the efficacy of the combined modality treatment including neoadjuvant chemoradiotherapy followed by D2  gastrectomy for patients with locally advanced gastric cancer. The  main inclusion criteria were: histologically verified gastric cancer,  cT3-4N0, cT2-4N1-3; M0. Before starting neoadjuvant therapy, all  patients underwent thoracic and abdominal CT and laparoscopy to  exclude peritoneal carcinomatosis. A total dose of radiation therapy  was 45 Gy (1 + 1.5 Gy/fraction/day with a 4–5 hour interval)  concurrently with the modified CAPOX chemotherapy regimen.  Gastrectomy or subtotal resection of the stomach was planned 4-6  weeks after the completion of chemoradiotherapy. The toxicity  assessment of neoadjuvant chemoradiotherapy was performed using the NCI CTC scale, version 3.0. The assessment of hematological, hepatic and pancreatic toxicities was done.Results.Among the toxicity during and after completion of  neoadjuvant chemoradiotherapy, thrombocytopenia, neutropenia and leukopenia (grade 1–2) were the most common, requiring no  additional symptomatic therapy. Radiation therapy was completed in  45 (98 %) patients. Chemotherapy was completed in 42 (91 %)  patients. The median time between the completion of  chemoradiotherapy and surgery was 44 days. Surgery following  chemoradiotherapy was performed in 100 % of patients, including R0 resection in 93 % of patients.Conclusion.Preoperative chemoradiotherapy was well tolerated by  patients, could be completed in most cases and did not prevent  subsequent surgical treatment.

Sign in / Sign up

Export Citation Format

Share Document